JP-2022514354-A5 -

Dates

Publication Date

20221206

Application Date

20191220

Description

Other embodiments are discussed throughout this application. Any embodiment discussed in relation to one aspect is similarly applicable to other aspects, and vice versa. The embodiments in the Examples section are understood to be applicable to all aspects. Further objects, features, and advantages of the present invention will become apparent from the following detailed description. However, it should be understood that the detailed description and specific examples are given only as illustrations, while illustrating preferred embodiments of the present invention, since various changes and modifications within the spirit and scope of the invention are expected to become apparent to those skilled in the art from this detailed description. [Invention 1001] A method for treating cancer, comprising the step of administering to a subject with cancer an effective amount of a therapeutic composition containing one or more peptides that are 90-100% identical to SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or a peptide selected from their functional segments. [Invention 1002] The method of the present invention 1001, wherein the therapeutic composition is administered by injection. [Invention 1003] The method according to the present invention 1001, wherein the therapeutic composition is administered into a tumor. [Invention 1004] The method of the present invention 1001, wherein the cancer is bladder cancer, blood cancer, bone cancer, bone marrow cancer, brain/nervous system cancer, breast cancer, colorectal cancer, esophageal cancer, gastrointestinal cancer, head cancer, kidney cancer, liver cancer, lung cancer, nasopharyngeal cancer, cervical cancer, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, testicular cancer, tongue cancer, or uterine cancer. [Invention 1005] The method of the present invention 1001, wherein the peptide is present in doses of 0.001 mg/kg body weight and 10 mg/kg body weight, preferably at least 0.1 to 5 mg/kg body weight, up to 0.1 to 5 mg/kg body weight, or about 0.1 to 5 mg/kg body weight, most preferably 0.5 to 1 mg/kg body weight. [Invention 1006] The method of the present invention 1001, further comprising the step of administering a second anti-cancer treatment. [Invention 1007] The method of the present invention 1006, wherein the second anti-cancer treatment is chemotherapy, radiotherapy, immunotherapy, or anti-hormone therapy. [Invention 1008] The method of the present invention 1006, wherein the second anti-cancer treatment is ELANE protease. [Invention 1009] A method for inducing apoptosis in cancer cells, comprising the step of contacting cancer cells with an effective amount of one or more peptides having 90–100% identity with SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or a peptide selected from their functional segments. [Invention 1010] The method of the present invention 1009, wherein the cancer cells are present in a tumor of the bladder, blood, bone, bone marrow, brain/nervous system, breast, colorectal, esophagus, gastrointestinal tract, head, kidney, liver, lung, nasopharynx, neck, ovary, pancreas, prostate, skin, stomach, testis, tongue, or uterus. [Invention 1011] An anticancer peptide composition comprising one or more peptide components having 90-100% identity with SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or peptides selected from their functional segments. [Invention 1012] The composition of the present invention 1011, wherein the peptide has an amino acid sequence that is 90% identical to the amino acid sequence of SEQ ID NO:2. [Invention 1013] The composition of the present invention 1011, wherein the peptide has an amino acid sequence that is 90% identical to the amino acid sequence of SEQ ID NO:3. [Invention 1014] The composition of the present invention 1011, wherein the peptide has an amino acid sequence that is 90% identical to the amino acid sequence of SEQ ID NO:4. [Invention 1015] The composition of the present invention 1011, wherein the peptide component is bound to a substrate. [Invention 1016] The composition of the present invention 1015, wherein the substrate is a delivery vehicle. [Invention 1017] The composition of the present invention 1016, wherein the delivery vehicle is a nanoparticle.